🏅 Top traders

China doesn't approve drugs from other countries easily when they have their own drugs for covid, it can take a long time, so it's unlikely that approval will be completed by 2023.

Also this: https://www.manilatimes.net/2022/12/29/news/world/china-to-distribute-paxlovid-to-curb-surge/1872021

Pfizer's treatment received conditional approval from China's medical regulator in February 2022. The drug has been included in the coverage of the country's health insurance, 21jingji.com reported. Media reports said that in the early months of this year, over 20,000 boxes of Paxlovid were imported and distributed to Covid-19 medical treatment ...

@brp Wow, no kidding. I have never seen this or heard it before. I bet they have used all 20,000 boxes already!!

@brp Obviously, this won't count toward resolution. It has to be a new product approved during 2023. But my base rate has gone up considerably with this information. I wonder why don't they don't also approve the best vaccines??

@BTE Then you should rename the question to "in 2023" instead of "by 2023".

@brp I will do that for you, just because you insisted, but is it really not clearly implied for all markets that resolutions only include future events from the date of market creation? The Chinese approved Paxlovid in February 2022, so it is like good to know, and I am shocked it wasn't more widely reported in the US, but it isn't relevant to this market even as it is written originally.

https://www.cnn.com/2022/12/26/china/china-covid-beijing-paxlovid-distribution-intl-hnk/index.html

Chinese government already distributing Paxlovid.